Group 1 - DigitalBridge (DBRG) shares have increased by 7.9% over the past four weeks, closing at $8.74, with a mean price target of $16.65 indicating a potential upside of 90.5% [1] - The mean estimate consists of 10 short-term price targets with a standard deviation of $2.38, where the lowest estimate of $13 suggests a 48.7% increase, and the highest estimate predicts a surge of 128.8% to $20 [2] - Analysts show strong agreement on DBRG's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for DBRG's current year earnings has increased by 23.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - DBRG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [13]

Core Viewpoint - Confluent's stock has experienced significant declines following its first-quarter earnings report, primarily due to disappointing guidance for future growth despite positive revenue and income figures [1][2][3][4]. Financial Performance - Confluent reported double-digit percentage gains in both revenue and non-GAAP net income, exceeding average analyst expectations [3]. - The company's guidance for the year indicates lower growth in critical areas, particularly subscription revenue, which has raised concerns among investors [4]. Analyst Reactions - Following the earnings report, several analysts reduced their price targets for Confluent, with Needham's Mike Cikos lowering his target from $40 to $26 while maintaining a buy recommendation [5]. - The overall sentiment among analysts appears to be cautious, reflecting concerns over the company's growth trajectory [5]. Market Sentiment - The market reacted negatively to Confluent's earnings report, leading to a significant sell-off despite the company posting strong trailing results [2][3]. - There is a perception that Confluent may be oversold, presenting a potential opportunity for investors amid the current share price weakness [6].

Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) have gained 6.4% over the past four weeks to close the last trading session at $30.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $63.21 indicates a potential upside of 107.5%.The average comprises 14 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $23.20. While the low ...

NovoCure (NVCR) closed the last trading session at $18.31, gaining 2.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.14 indicates a 91.9% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $6.74. While the lowest estimate of $27 indicates a 47.5% increase from the current price level, the most optimistic analyst expects t ...

Shares of Impinj (PI) have gained 0.2% over the past four weeks to close the last trading session at $90.84, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $149.50 indicates a potential upside of 64.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $55.04. While the lowest estimate of $100 indicates a 10.1% increase from the current pric ...

First Business Financial Services (FBIZ) closed the last trading session at $47.69, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $60.20 indicates a 26.2% upside potential.The average comprises five short-term price targets ranging from a low of $57 to a high of $62, with a standard deviation of $2.05. While the lowest estimate indicates an increase of 19.5% from the ...

Core Viewpoint - ASML shares have shown a modest gain of 0.4% over the past four weeks, closing at $677.27, with a mean price target of $916.63 indicating a potential upside of 35.3% according to Wall Street analysts [1][11]. Price Targets and Analyst Consensus - The mean estimate consists of eight short-term price targets with a standard deviation of $95.86, suggesting variability in analyst predictions [2]. - The lowest price target of $835 indicates a 23.3% increase from the current price, while the highest target of $1,100 suggests a potential surge of 62.4% [2]. - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ASML's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has risen by 7.3% over the past month, with six estimates increasing and no negative revisions [12]. - ASML holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].

Shares of Enova International (ENVA) have gained 1.8% over the past four weeks to close the last trading session at $97.88, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $127.71 indicates a potential upside of 30.5%.The average comprises seven short-term price targets ranging from a low of $109 to a high of $138, with a standard deviation of $10.80. While the lowest estimate i ...

Shares of South Plains Financial (SPFI) have gained 1.9% over the past four weeks to close the last trading session at $33.72, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $42.75 indicates a potential upside of 26.8%.The average comprises four short-term price targets ranging from a low of $39 to a high of $45, with a standard deviation of $2.63. While the lowest estimate ind ...

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]